Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia

Completed

• Conditions: Atrial Fibrillation
• Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)

• Registration Number: NCT01750788
• Lead Sponsor: Bayer

Brief Summary

This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-12-13
• Study First Submitted QC: 2012-12-13
• Study First Posted: 2012-12-17
• Study Start: 2013-01-13
• Primary Completion: 2015-10-12
• Study Completion: 2015-10-12
• Status Verified: 2017-09
• Last Update Submitted: 2017-09-20
• Last Update Posted: 2017-09-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2297

Inclusion Criteria

• Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS (Central Nervous System) systemic embolism, and who consent to participate in the study.

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group 1	Rivaroxaban (Xarelto, BAY59-7939)	-

Primary Outcome Measures

Name	Time	Method
Adjudicated major bleeding events	after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Safety variables will be summarized using descriptive statistics based on adverse events collection	after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
All cause mortality	after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later

Secondary Outcome Measures

Name	Time	Method
Healthcare resource	after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later	Number of healthcare professional visits and hospitalizations due to anticoagulation
Adverse events rates in the different AF risk factor categories	after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Adjudicated symptomatic thromboembolic events	after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Non-major bleeding, collected as SAEs or non-serious AEs and defined as all bleeding events that do not fall in the category of major bleedings	after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Persistence with rivaroxaban treatment measured as percentage of patients on rivaroxaban treatment at 1 year after start of study treatment	after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Reasons for switch of rivaroxaban treatment as per physician assessment during or at end of study	after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Treatment satisfaction as per patient assessment of rivaroxaban treatment by the physician at the final visit	after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later
Reasons for interruption of rivaroxaban treatment as per physician assessment during or at end of study	after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later